Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-09-18

FDA Approved: RISPERIDONE — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for risperidone by Jubilant Cadista Pharmaceuticals Inc., updating/expanding its approval for risperidone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RISPERIDONE (RISPERIDONE)

Snippet

SUPPL AP for RISPERIDONE (RISPERIDONE)